Intellia Therapeutics, Inc. (NASDAQ:NTLA) has released positive new clinical data from the ongoing phase 1 trial of Nexiguran Ziclumeran (Nex-Z), also known as NTLA-2001, in patients with ...
As BridgeBio approaches its FDA target date for approval of TTR stabilizer acoramidis to treat the rare heart disease ...
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company ...
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Medpage Today on MSN1d
Novel CRISPR-Cas9-Based Promising in ATTR CardiomyopathyA CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...
In recent trading, Intellia Therapeutics Inc (NTLA) stock price has shown some volatility, fluctuating -16.50% over the last five trades and -33.41% over the past 30 trades. This represents a notable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback